PET-CT in pancreatic cancer — when the scan is actually used

Most people arrive at this page after typing “pet ct pancreatic cancer” into a search box, usually because the scan has just been mentioned in a clinic room, or because it has not been mentioned and they are wondering why. A PET-CT combines two studies in one appointment. The CT half maps anatomy. The PET half maps activity: a small amount of a glucose-analogue tracer is injected, cells that are consuming sugar quickly take up more of it, and the scanner shows where it has gathered. Cancer cells are often, though not always, among the hungriest cells in the body, so they can stand out against the tissue around them.

That sounds like it should be the definitive scan. In pancreatic cancer, it is not, and the reason is worth understanding before you push for one. The scan that decides almost everything at the start is a timed, contrast-enhanced pancreatic-protocol CT scan, because the question that dominates the first few weeks is whether the tumour has grown around the arteries and veins that sit directly behind the pancreas. A PET-CT cannot answer that question. Uptake tells you something about how a lesion is behaving; it tells you very little about millimetres of contact with a vessel wall, and it is millimetres of contact that decide whether an operation is possible.

What a PET-CT does bring is reach. It looks at the whole body in one pass rather than at one region, so it can find activity somewhere nobody had aimed a scanner — a node above the diaphragm, a bone, a second liver lesion in a segment the CT clipped. That matters most at exactly one decision point: when someone is being prepared for major surgery or a course of treatment given with the intention of cure, and a hidden deposit elsewhere would change that plan completely.

It is also worth saying plainly what an avid area is not. It is not a diagnosis. Inflamed tissue burns sugar too, so pancreatitis, infection, a recently placed stent and healing after a biopsy can all light up convincingly. Nor is a quiet scan an all-clear: some pancreatic tumours are simply not very avid, small deposits sit below the resolution of any scanner, and a well-differentiated neuroendocrine tumour usually needs a completely different study, described in DOTATATE PET-CT for neuroendocrine tumours. A PET scan for pancreatic cancer is read next to your CT, your bloods and your biopsy. It is never read alone.

• Inflammation looks like cancer. Pancreatitis, an infection, a recently placed biliary stent or the healing track after a biopsy can all take up tracer avidly. A bright pancreas is not, on its own, a malignant pancreas.
• Some pancreatic tumours are quiet. Uptake varies with the biology of the tumour. A lesion that stays dark on the scan has not been excluded — it has only failed to declare itself on this particular test.
• Small-volume spread hides. A thin sheet of disease on the peritoneal surface is a common reason for a planned operation to be abandoned, and it is frequently invisible on every scan, which is why staging laparoscopy still exists as a separate step.
• Blood sugar changes the picture. The tracer competes with the sugar already in your blood, so an uncontrolled glucose level degrades the study. This matters more in pancreatic disease than almost anywhere else, because new or type 3c diabetes is so often part of the picture.
• Recent treatment confuses it. Tissue that has just had radiation or chemotherapy is inflamed, and inflamed tissue is metabolically busy. Timing the scan properly matters as much as ordering it.
• It cannot judge the vessels. Arterial and venous contact, the finding that decides whether surgery is possible, is a contrast-CT question and stays one. The full detail is on the pancreatic-protocol CT scan page.
• It is not a screening test. A PET-CT is not used to look for pancreatic cancer in someone who is well, and a normal one is not a certificate of health. The wider diagnostic pathway is set out in our complete guide to pancreatic cancer.

1. 1

   The decision is made at CION

   Your oncologist works out whether the result would change anything — using your contrast CT, your bloods and, where it exists, your biopsy. If the answer would not alter the plan, we will say so rather than add a test to the file.

   In-house at CION
2. 2

   The scan is booked at a partner centre

   A PET-CT needs a licensed nuclear-medicine unit and a tracer prepared on the day. CION does not run one, and we would rather tell you that plainly. We arrange the appointment with a partner nuclear-medicine centre, and that part of your care is billed there.

   Coordinated with a partner nuclear-medicine centre
3. 3

   Preparation is confirmed with you

   You will be asked to fast beforehand and to avoid strenuous activity the day before, because working muscle takes up tracer too. If you have diabetes, the centre will want your blood sugar reasonably controlled on the day, and will tell you what to do about your usual medication and timings.

   Coordinated with a partner nuclear-medicine centre
4. 4

   The day itself

   The tracer is injected, then there is a quiet wait in a room while it distributes, and then the scan, which asks only that you lie still. Most people are at the centre for a few hours in total and go home afterwards. You are not admitted and you do not need anyone to drive you.

   Coordinated with a partner nuclear-medicine centre
5. 5

   The images come back to your oncologist

   We read them against your CT or MRI and your pathology and take the case to a tumour board, rather than acting on a single report in isolation. How the study itself works in general is covered on our PET-CT scan page.

   In-house at CION
6. 6

   What it means is explained to you in person

   An avid area is not a verdict and a quiet scan is not a discharge. You get the finding, what it changes, what it does not change, and the next step, said in plain language and written down for you to take away.

   In-house at CION

This is practical rather than legal detail, because it decides where you travel and who invoices you. CION has no nuclear-medicine unit of its own. Every PET-CT study, including receptor imaging for neuroendocrine tumours and receptor-targeted radionuclide therapy, is coordinated with partner nuclear-medicine centres and may be billed by them rather than by us. In the same way, endoscopic ultrasound and biopsy, ERCP and any biliary or duodenal stenting, staging laparoscopy, a coeliac plexus block for pain, and all pancreatic surgery are coordinated with specialist hepatobiliary, gastroenterology and endoscopy partners.

What happens at CION is everything around the scan, which on a pancreatic pathway is most of the journey. Deciding whether the study is worth doing at all. Reading it against your contrast CT, your MRI and your pathology. The tumour board. Chemotherapy before or after surgery and for advanced disease, radiation, chemoradiation and stereotactic radiotherapy, delivered in-house across 35+ centres. Pancreatic-protocol CT, MRI and MRCP, CA 19-9 and routine bloods, ordered and reported by us. Genetic counselling where the family history warrants it, nutrition and pancreatic enzyme support, pain and psycho-oncology care, and long-term follow-up once treatment settles.

• A free 45-minute consultation, with your scans opened and read in front of you rather than summarised back at you from a report.
• A straight answer on whether a PET-CT would change your management — and if it would not, we will tell you that instead of adding a scan.
• A written split of what the partner centre bills and what CION bills, before anything is booked.
• Aarogyasri, NTR Vaidya Seva and insurance routes checked against each part of the pathway, not only against the treatment.
• If the question is really about a neuroendocrine tumour, the right study is a receptor scan — explained in DOTATATE PET-CT for neuroendocrine tumours.
• Systemic therapy, radiation, nutrition and supportive care delivered in-house, with the options set out in pancreatic cancer treatment in Hyderabad.

Medical disclaimer: This page explains when a PET-CT is and is not useful in pancreatic cancer and how the study fits with the rest of the imaging pathway, and is reviewed by a CION medical oncologist with reference to NCCN guidance on pancreatic adenocarcinoma. It is general information and not a substitute for an individual radiological or oncological opinion; whether this scan is appropriate for you depends on your own imaging, pathology and treatment plan, and must be decided with your treating team. Pancreatic-protocol CT, MRI and MRCP, CA 19-9 and bloods, tumour-board planning, chemotherapy, radiation, chemoradiation and stereotactic radiotherapy, genetic counselling, nutrition and pancreatic enzyme support, pain and psycho-oncology care and survivorship follow-up are delivered by CION. All PET-CT studies, including receptor imaging, and receptor-targeted radionuclide therapy are coordinated with partner nuclear-medicine centres, and endoscopic ultrasound and biopsy, ERCP and biliary or duodenal stenting, staging laparoscopy, coeliac plexus block and all pancreatic surgery are coordinated with specialist hepatobiliary, gastroenterology and endoscopy partner centres; each of these may be billed there.